CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for ...

As it plows ahead in its efforts to secure an FDA greenlight for its light- and sound-based neuromodulation device to treat Alzheimer’s disease, Cognito Therapeutics is taking an even closer look at ...

For decades, biotech companies have struggled to develop treatments for Alzheimer's disease, a disorder that causes loss of memory and other mental functions and affects roughly 6.5 million Americans.

Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...

Collaboration expands national initiative designed to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies Cognito Therapeutics, a late clinical-stage ...

Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX Ventures, bringing its total ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

Please provide your email address to receive an email when new articles are posted on . Cognito Therapeutics and Providence Health Plan will collaborate on a phase 3 study of a noninvasive therapy for ...

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

CAMBRIDGE, Mass. and NEW ORLEANS – March 25, 2026 - Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...